Current reports
8-K
3 Agenda ▪ Business Update ▪ Our Research Strategy ▪ Our Platform ▪ Lead Candidates ▪ Forward Looking ▪ Closing Remarks ▪ Q&A
9 Apr 24
8-K
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
13 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
8-K
Entry into a Material Definitive Agreement
24 Jan 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Other Events
4 Jan 24
8-K
ADC Therapeutics Provides Business Updates
4 Jan 24
6-K
Current report (foreign)
19 Dec 23
6-K
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
7 Nov 23
Registration and prospectus
424B3
Prospectus supplement
15 Mar 24
424B3
Prospectus supplement
15 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
S-8
Registration of securities for employees
18 Dec 23
S-8
Registration of securities for employees
4 Dec 23
SC TO-I/A
Issuer tender offer statement (amended)
5 Apr 23
SC TO-I/A
Issuer tender offer statement (amended)
30 Mar 23
SC TO-I/A
Issuer tender offer statement (amended)
29 Mar 23
Other
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
27 Mar 23
EFFECT
Notice of effectiveness
21 Mar 23
CORRESP
Correspondence with SEC
21 Mar 23
UPLOAD
Letter from SEC
21 Mar 23
CORRESP
Correspondence with SEC
16 Mar 23
UPLOAD
Letter from SEC
14 Mar 23
EFFECT
Notice of effectiveness
19 Sep 22
Ownership
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
25 Apr 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
ASTRAZENECA PLC
12 Feb 24
4
Jeremy Green
9 Feb 24
3
Jeremy Green
9 Feb 24
3
Viviane Monges
2 Jan 24
3
Jose Carmona
2 Jan 24
3
PETER J GRAHAM
2 Jan 24
3
JEAN-PIERRE BIZZARI
2 Jan 24